Get startedLog in
    Picture of Perspective Therapeutics logo

    CATX — Perspective Therapeutics Income Statement

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeSmall CapNeutral
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for Perspective Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

    2020
    June 30th
    2021
    June 30th
    2022
    June 30th
    2023
    December 31st
    2024
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:10-K10-K10-K10-K10-K
    Standards:
    USG
    USG
    USG
    USG
    USG
    Status:FinalFinalFinalFinalFinal
    Revenue
    Total Revenue9.6810.110.81.431.45
    Cost of Revenue
    Gross Profit5.125.124.62——
    Selling / General / Administrative Expenses
    Research And Development
    Unusual Expense / Income
    Other Operating Expenses
    Total Operating Expenses13.213.518.242.492.3
    Operating Profit-3.48-3.45-7.39-40.9-90.9
    Total Net Non Operating Interest Income / Expense
    Other Net Non Operating Costs
    Net Income Before Taxes-3.45-3.39-7.27-40.1-80.4
    Provision for Income Taxes
    Net Income After Taxes-3.45-3.39-7.27-37.5-78.3
    Net Income Before Extraordinary Items
    Extraordinary Items
    Net Income-3.45-3.39-7.27-46.5-79.3
    Adjustments to Net Income
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Diluted Net Income-3.46-3.39-7.27-46.5-79.3
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS-0.511-0.326-0.512-1.4-0.973